Table 3.
Immunophenotypic characteristics of CD16+ and CD16– monocytes in the study participants categorized by BMI and by WC
| BMI |
WC |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| F | df | NW | OW | OB | p | F | df | without CO | with CO | p | |
| F/M (n) | 9/7 | 12/21 | 7/7 | 0.377a | 3/14 | 25/21 | 0.009a | ||||
| Cells/μl | |||||||||||
| CD16+ | 0.371 | 2, 59 | 53 ± 68 | 48 ± 29 | 62 ± 70 | 0.011 | 1, 60 | 51 ± 66 | 53 ± 45 | ||
| CD16− | 0.227 | 2, 59 | 369 ± 145 | 397 ± 141 | 386 ± 106 | 2.165 | 1, 60 | 428 ± 137 | 372 ± 131 | ||
| Ratio CD16+/CD16– | 0.313 | 2, 59 | 0.14 ± 0.10 | 0.13 ± 0.07 | 0.15 ± 0.14 | NS | 1.076 | 1, 60 | 0.11 ± 0.10 | 0.14 ± 0.10 | NS |
| % cells | |||||||||||
| CD16+ | 0.160 | 2, 59 | 11.6 ± 7.2 | 11.0 ± 5.5 | 12.2 ± 9.4 | 1.437 | 1, 60 | 9.7 ± 6.9 | 12.0 ± 6.7 | ||
| CD16− | 0.160 | 2, 59 | 88.4 ± 7.2 | 89.0 ± 5.5 | 87.8 ± 9.4 | 1.432 | 1, 60 | 90.3 ± 6.9 | 88.0 ± 6.7 | ||
| Ratio CD16+/CD16− | 0.306 | 2, 59 | 0.14 ± 0.10 | 0.13 ± 0.08 | 0.15 ± 0.14 | NS | 1.045 | 1, 60 | 0.11 ± 0.10 | 0.14 ± 0.10 | NS |
| FSC | |||||||||||
| CD16+ | 0.615 | 2, 59 | 570 ± 59 | 556 ± 71 | 544 ± 53 | 0.005 | 1, 60 | 558 ± 71 | 557 ± 63 | ||
| CD16− | 0.837 | 2, 59 | 571 ± 60 | 555 ± 67 | 540 ± 55 | 0.064 | 1, 60 | 559 ± 16 | 555 ± 62 | ||
| Ratio CD16+/CD16− | 0.257 | 2, 59 | 1.0 ± 0.04 | 1.0 ± 0.03 | 1.01 ± 0.03 | NS | 0.755 | 1, 60 | 1.0 ± 0.02 | 1.0 ± 0.003 | NS |
| SSC | |||||||||||
| CD16+ | 0.784 | 2, 59 | 424 ± 48 | 406 ± 57 | 404 ± 46 | 3.799 | 1, 60 | 431 ± 58 | 402 ± 49 | ||
| CD16− | 0.938 | 2, 59 | 494 ± 37 | 477 ± 51 | 476 ± 38 | 0.354 | 1, 60 | 487 ± 46 | 479 ± 45 | ||
| Ratio CD16+/CD16− | 0.213 | 2, 59 | 0.86 ± 0.07 | 0.85 ± 0.05 | 0.84 ± 0.04 | NS | 9.356 | 1, 60 | 0.88 ± 0.06 | 0.84 ± 0.05 | 0.003 |
| CD14 | |||||||||||
| CD16+ | 0.226 | 2, 55 | 976 ± 691 | 863 ± 529 | 861 ± 473 | 1.191 | 1, 60 | 1027 ± 626 | 845 ± 532 | ||
| CD16− | 1.354 | 2, 58 | 2,855 ± 2,055 | 2,194 ± 1,331 | 2,292 ± 1,161 | 0.299 | 1, 60 | 2,116 ± 332 | 2,362 ± 240 | ||
| Ratio CD16+/CD16− | 1.051 | 2, 59 | 0.37 ± 0.17 | 0.43 ± 0.18 | 0.36 ± 0.11 | NS | 6.003 | 1, 60 | 0.48 ± 0.19 | 0.37 ± 0.15 | 0.017 |
| CD36 | |||||||||||
| CD16+ | 0.004 | 2, 59 | 315 ± 194 | 316 ± 120 | 320 ± 110 | 0.060 | 1, 60 | 324 ± 190 | 313 ± 116 | ||
| CD16− | 0.720 | 2, 59 | 755 ± 196 | 713 ± 221 | 790 ± 175 | 1.926 | 1, 60 | 681 ± 250 | 762 ± 184 | ||
| Ratio CD16+/CD16− | 1.191 | 2, 59 | 0.41 ± 0.16 | 0.47 ± 0.16 | 0.40 ± 0.08 | NS | 2.544 | 1, 60 | 0.49 ± 0.04 | 0.42 ± 0.02 | NS |
| CD11b | |||||||||||
| CD16+ | 1.745 | 2, 27- | 121 ± 97 | 70 ± 63 | 59 ± 25 | 0.059 | 1, 28 | 87 ± 63 | 80 ± 76 | ||
| CD16− | 3.817 | 2, 27 | 442 ± 492 | 127 ± 147 | 132 ± 49 | 0.091 | 1, 28 | 184 ± 181 | 222 ± 72 | ||
| Ratio CD16+/CD16− | 2.978 | 2, 27 | 0.44 ± 0.22 | 0.71 ± 0.36 | 0.45 ± 0.11 | NS | 0.094 | 1, 28 | 0.62 ± 0.22 | 0.58 ± 0.08 | NS |
F = Snedcor's distribution; df= degree of freedom; NS = not significant.
The median fluorescence intensities of CD14, CD36, and CD11b were assessed in each subset and expressed as fluorescence arbitrary units. Data are presented as mean ± SD or aspercentage, as appropriate. ANOVA with correction with post hoc Bonferroni teste was used for comparison between the 3 BMI groups. Significant differences are given in italics.
a
Pearson chi-square test was used to determine differences of F/M (female/male).